Investigation of Tigecycline Susceptibility of Multidrug-Resistant Acinetobacter Baumannii Isolates by Disc Diffusion, Agar Gradient and Broth Microdilution Tests

Çalışkan, Emel

doi:10.20471/acc.2022.61.01.06

Cited by 1 publication

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Susceptibility to tigecycline was determined according to FDA criteria for Enterobacteriaceae. 15 Colistin MICs were determined by a broth microdilution method, (MICs ≤2 mg/L as intermediate and ≥4 mg/L as resistant) as per CLSI guidelines (edition 31). 16 We did not check molecular resistance mechanism for carbapenemase production.…”

Section: Methodsmentioning

confidence: 99%

Outcome, risk factors and therapeutic strategies in carbapenem-resistant Gram-negative bacteraemia from Pakistan

Fatima

Dodani

Babar

et al. 2023

JAC-Antimicrobial Resistance

View full text Add to dashboard Cite

Background Carbapenem-resistant Gram-negative (CRGN) bacteraemia has high mortality and limited therapeutic options. We assessed the risk factors and outcome of CRGN bacteraemia treated with limited options. Methods A prospective cohort study done at a tertiary care hospital in Pakistan, from October 2021 to August 2022. All patients >18 years with CRGN bacteraemia were assessed for demographics, source, risk factors and treatment received. Outcome was assessed as bacterial clearance and all-cause mortality at Day 14 of bacteraemia. Results We included 175 patients. Median age was 45 years (IQR 30–58) and the majority of our patients were on haemodialysis (75%). We found 14 day mortality in 26.8% of our patients; in addition, microbiological clearance was achieved in 95%. The central line (49.7%) was the most common source and Klebsiella spp. (47%) the most common organism. On multivariate analysis, risk factors for mortality were Foley’s catheter [aOR 2.7 (95% CI 1.1–6.5)], mechanical ventilation [aOR 5.1 (95% CI 1.6–15.8)] and Pitt bacteraemia score >4 [aOR 3.48 (95% CI 1.1–10.5)]. Source control was a significant protective factor [aOR 0.251 (95% CI 0.09–0.6)]. The majority received a colistin-based regimen with no difference in mortality between monotherapy and combination therapy. Conclusions Our cohort of CRGN bacteraemia is unique, comprising younger patients mostly on haemodialysis with a central line as the source of bacteraemia and we have found 14 day mortality of 27%. Colistin with various combinations can be an effective option in patients with renal failure having prompt source control.

show abstract

Section: Methodsmentioning

confidence: 99%